Together, we can transform the future of cancer care.
Tracking early stage breast cancer with ultrasensitive ctDNA
Information for patients with breast cancer
Monitoring therapy response with ultrasensitive ctDNA across cancer types
Ultrasensitive ctDNA detection in early-stage lung cancer
Personalis is transforming the development of next-generation therapies.
These teams of passionate people are working with us to build the next standard of care in oncology. Read more about our collaborations and partnerships.
Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials
Personalis and UCSF to Study Clinical Utility of ctDNA for Treatment Response in Colorectal Cancer
Personalis Forms Research Collaboration to Better Predict Immunotherapy Response for Gastroesophageal Cancer
Personalis and BC Cancer to Assess Clinical and Economic Benefits of ctDNA for Colorectal and Pancreatic Cancers
Evaxion to Utilize Personalis’ ImmunoID NeXT Platform® to Evaluate Efficacy of Combination Therapy for Late-Stage Melanoma
Personalis and Merck KGaA, Darmstadt, Germany Collaborate to Present Comprehensive Tumor Subtyping Collaboration Data
Personalis and UC San Diego Moores Cancer Center Collaborate for Clinical Genomic Testing and Research into Composite Biomarkers and Minimal Residual Disease Detection
